SCHEMBL5639167

SCHEMBL5639167

O=CN[C@H]1CCCCN(C(=O)Oc2ccccc2)C1=O

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.43
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ CHRNA7 P36544 1/20 0.40
▸ HTR3A P46098 1/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ POLB P06746 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5638131 0.88 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2GAARAB9AMEN1
SCHEMBL5639158 0.83 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPK1KDM4EGAA
SCHEMBL5640756 0.82 KDM4E (0.49) ALDH1A1SMN1; SMN2KDM4EGAARAB9A
SCHEMBL5640334 0.81 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2KDM4EGAARAB9A
SCHEMBL5637467 0.81 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2KDM4EGAAPOLB
SCHEMBL5640869 0.80 NAAA (0.39) ALDH1A1KDM4EMEN1KMT2A
SCHEMBL5637058 0.78 ALDH1A1 (0.48) ALDH1A1KDM4EPOLB
SCHEMBL5638512 0.77 THRB (0.43) ALDH1A1SMN1; SMN2MAPK1KDM4EGAA
SCHEMBL5639328 0.76 HPGD (0.37) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL5638425 0.75 KMT2A (0.43) ALDH1A1SMN1; SMN2KDM4EGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 — — EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 ALDH1A1 1286/4885SMN1; SMN2 4121/4885MAPK1 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback